Company intelligence / Profile preview

Deepsonbio

Chuncheon-si, Gangwon-do, South Koreadeepsonbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

In an exploratory clinical trial using the NEUCLARE device on patients with normal pressure hydrocephalus, statistically significant improvements in mobility were observed after three sessions. The company plans to expedite pivotal trials for both NPH and Alzheimer's based on these results. No commercial-stage products yet.

Therapeutic areas: OncologyNeurology
Modalities: Device (Therapeutic ultrasound device)Non-invasive therapy device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

NEUCLARE

Phase 1

Indications: Normal pressure hydrocephalus, Alzheimer's disease

Beyond the preview

Go deeper on Deepsonbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deepsonbio.

Explore the full profile